Glutathione

What Glutathione is

Glutathione (L-γ-glutamyl-L-cysteinyl-glycine, CAS 70-18-8) is a low-molecular-weight tripeptide classified as an endogenous non-protein thiol compound. It was first described in 1888 by J. De-Rey Pailhade, who isolated it from various biological sources including blood and brain tissue and named it 'philothion' — Greek for 'sulfur-loving' ^[1]. Its full structural characterisation as a tripeptide, γ-L-glutamyl-L-cysteinylglycine, was established by Sir Frederick Gowland Hopkins in the early 1920s, earning him recognition as a founder of modern biochemistry ^[2]. The cellular glutathione biosynthesis cycle — a two-step, ATP-dependent process catalysed sequentially by γ-glutamylcysteinyl ligase (GCL) and glutathione synthase — was mapped in the 1970s by Alton Meister, establishing the mechanistic framework that underpins all contemporary GSH research ^[3].

Glutathione is ubiquitous: it is found in essentially every nucleated cell in the body, from bacteria to mammals, and is present at particularly high concentrations in the liver, where detoxification demands are greatest ^[4]. Its defining chemical feature is a free thiol group (–SH) on its cysteine residue, which can be reversibly oxidised to glutathione disulfide (GSSG), a property that makes the GSH/GSSG ratio a widely used index of cellular redox status ^[3]. Today, glutathione is one of the most extensively studied molecules in all of biochemistry and cell biology ^[3].

What it is being researched for

1. Cellular Redox Homeostasis and Antioxidant Defence

Glutathione is studied as the cell's master intracellular antioxidant. Reactive oxygen species (ROS) — including superoxide anions, hydrogen peroxide, and hydroxyl radicals — arise as by-products of normal oxidative metabolism and, when they accumulate beyond the cell's clearance capacity, cause oxidative stress and biomolecular damage ^[5]. GSH neutralises ROS by donating electrons through a redox cycle: oxidised GSH (GSSG) is continuously recycled back to the active reduced form (GSH) by the enzyme glutathione reductase, sustaining a high intracellular GSH/GSSG ratio ^[3]. Research using cell lines and animal models shows that depletion of GSH compromises this buffer, while restoration of GSH levels attenuates oxidative injury — findings that motivate ongoing research into conditions ranging from ischemia-reperfusion injury to metabolic disease ^[5].

2. Skin Pigmentation and Anti-Ageing Research

Glutathione is intensively investigated for its ability to modulate melanin synthesis, and several randomised controlled trials (RCTs) have examined both oral and topical formulations in healthy volunteers ^[6]. In vitro evidence indicates GSH may inhibit tyrosinase — the rate-limiting enzyme in melanin production — and promote a shift from darker eumelanin toward lighter pheomelanin ^[7]. A double-blind, placebo-controlled RCT in Filipino women using a 2% topical oxidised glutathione (GSSG) lotion over ten weeks found a statistically significant reduction in melanin index compared with placebo, along with improvements in skin moisture, smoothness, elasticity, and wrinkle formation ^[8]. A 2025 systematic review of five RCTs on oral GSH likewise reported significant reductions in melanin index versus placebo, while noting that the combination of topical and oral glutathione outperformed either approach alone and that any pigmentation changes appear to be reversible upon discontinuation ^[6]. Researchers continue to flag the small sample sizes, short durations, and limited generalisability of current trials as significant gaps in the evidence base ^[7].

3. Liver Health and Detoxification

GSH is especially relevant to hepatic research because the liver is the organ most intensively exposed to ingested toxins and metabolic by-products ^[4]. Research demonstrates that GSH fulfils several essential hepatic functions: detoxification of free radicals and toxic oxygen species, thiol–disulfide exchange, and conjugation with xenobiotics to render them water-soluble for excretion ^[4]. A 2025 literature review of human studies (2014–2024) on GSH therapy in non-alcoholic fatty liver disease (NAFLD) analysed three trials totalling 109 participants and found consistent improvements in alanine transaminase (ALT) levels — a liver enzyme marker — and reductions in oxidative stress biomarkers such as 8-OHdG, though the authors emphasised that small sample sizes and inconsistent protocols limit generalisability and that larger RCTs are required ^[9]. An earlier open-label, single-arm, multicentre pilot study also reported significant decreases in ALT following a course of oral glutathione in NAFLD patients ^[10].

4. Ageing, Mitochondrial Function, and Longevity Research

Research from Baylor College of Medicine has shown that older adults have severely deficient intracellular GSH compared with younger adults — primarily due to diminished synthesis caused by reduced availability of the precursor amino acids glycine and cysteine ^[11]. A placebo-controlled RCT supplementing older adults with GlyNAC (glycine plus N-acetylcysteine, the precursors needed for GSH synthesis) for 16 weeks found that correcting GSH deficiency was associated with improvements in mitochondrial function, oxidative stress, inflammation, insulin resistance, endothelial function, muscle strength, gait speed, and cognitive measures — multiple hallmarks of ageing — compared with placebo ^[11]. These findings position glutathione deficiency as a potential upstream contributor to age-related functional decline and have stimulated interest in GSH precursor strategies as a research target in geroscience ^[11].

5. Immune System Modulation

Glutathione is recognised as integral to immune regulation through its roles in maintaining redox balance across immune cell types and modulating inflammatory signalling pathways ^[12]. Research indicates that reduced GSH is required for normal T-lymphocyte proliferation, the phagocytic activity of neutrophils, dendritic cell function, and effective antigen presentation ^[12]. Disturbances in GSH metabolism have been associated in the research literature with impaired immune responses and with conditions characterised by chronic inflammation ^[5]. Much of this work remains at the cell-culture and animal-model stage, and translation to clinical immunological outcomes in humans requires further investigation.

6. Neuroprotection and Neurodegenerative Disease Research

GSH is described in the neuroscience literature as an important antioxidant in the brain, where it scavenges ROS and reactive nitrogen species (RNS) generated during neuronal metabolism and detoxifies potentially damaging compounds ^[12]. Researchers have explored a possible therapeutic role in conditions such as Alzheimer's disease and Parkinson's disease, where oxidative stress and depleted brain GSH are consistently observed ^[13]. GSH also interacts with glutamate — the brain's principal excitatory neurotransmitter — and is thought to help limit glutamate-related excitotoxicity ^[12]. The majority of mechanistic evidence in this area comes from cell and animal studies; robust clinical trials in neurological conditions are limited and represent a clear research gap.

7. Cardiovascular Redox Research

Glutathione is studied as the most abundant antioxidant in the heart, where it is thought to protect cardiomyocytes from oxidative damage and to participate in redox signalling via a process called protein glutathionylation — the reversible formation of mixed disulfide bonds between GSH and cysteine residues of cardiac proteins ^[5]. A community-based case-control study (the Hisayama Study, 134 CVD cases and 435 matched controls) found that lower plasma GSH concentrations were significantly associated with cardiovascular disease risk, including cerebral infarction and cerebral haemorrhage, after adjustment for confounding factors ^[14]. Preclinical work in aged rat models has shown that exogenous glutathione can restore mitochondrial redox status and improve cardiovascular parameters including endothelium-dependent vasorelaxation ^[15]. Human intervention data remains limited.

How it is thought to work

Glutathione exerts its primary antioxidant effect through its free thiol group (–SH), which donates hydrogen atoms to neutralise reactive oxygen species such as hydrogen peroxide, superoxide radicals, and lipid peroxides. When GSH reduces these oxidants, it is itself oxidised to glutathione disulfide (GSSG). The cell then relies on the enzyme glutathione reductase — using NADPH as a cofactor — to regenerate GSH from GSSG, sustaining a continuous supply of active antioxidant and maintaining the GSH/GSSG ratio at approximately 100:1 under healthy conditions ^[3]. This cyclical redox reaction constitutes the core of the cellular glutathione redox cycle and is the main mechanism by which GSH buffers the cell against oxidative damage ^[3].

Beyond direct radical scavenging, GSH is integral to a wider set of cellular protection mechanisms. It conjugates with electrophilic xenobiotics and reactive metabolites — catalysed by the glutathione S-transferase (GST) enzyme family — to form water-soluble conjugates that are more readily excreted, a process central to hepatic detoxification ^[4]. In the context of skin research, GSH is thought to inhibit tyrosinase activity, limiting the oxidation of tyrosine to dopaquinone, an early step in melanin biosynthesis; it may also redirect melanogenesis toward lighter pheomelanin ^[7]. Additionally, GSH participates in protein glutathionylation — the reversible attachment of a glutathione molecule to protein cysteine residues — which functions as a molecular switch for regulating protein function in response to oxidative signals ^[5]. Research into the NRF2 transcription-factor pathway further shows that GSH and GSH-dependent enzymes can upregulate the cell's broader antioxidant gene-expression programme, amplifying protection beyond the immediate thiol-based scavenging reaction ^[9].

Where the evidence stands

The published evidence base for glutathione spans in vitro cell studies, animal experiments, and a growing but still limited number of human clinical trials. At the cell and animal level, evidence is relatively consistent: GSH depletion reproducibly increases oxidative damage and cell death across diverse model systems, while restoration of GSH levels attenuates these effects; hepatoprotective, neuroprotective, and cardioprotective outcomes have been demonstrated in multiple rodent models ^[9][5][15]. At the human clinical level, the picture is more mixed. In the skin-lightening domain, a 2025 systematic review identified five RCTs showing statistically significant reductions in melanin index with oral GSH, and topical GSSG has shown significant effects in a double-blind split-face RCT, though all pigmentation changes appear reversible and study populations are limited largely to Asian skin types ^[6][8]. In NAFLD, a small body of human trial data (totalling ~109 participants across three studies) shows consistent improvement in liver enzyme markers and oxidative stress biomarkers, but the sample sizes are too small to support confident clinical conclusions ^[9]. The GlyNAC ageing programme has produced two noteworthy RCTs demonstrating that correcting GSH deficiency by supplementing precursors improved multiple ageing-related biomarkers in older adults, though these trials were similarly small and precursor-based rather than direct GSH administration ^[11].

Several important limitations cut across the literature. Direct oral GSH is partially degraded in the gastrointestinal tract before systemic absorption, with the molecule broken down into its component amino acids; this complicates dose–response interpretation and makes it difficult to compare oral and systemic delivery routes ^[7]. The majority of trials are short-term (4–16 weeks), involve small participant numbers, and lack long-term safety data for sustained use ^[6][7]. The evidence on intravenous glutathione as a skin-whitening agent specifically has been described as unclear due to the absence of rigorous clinical trial data, and regulatory agencies in several countries have flagged IV glutathione for cosmetic purposes as not supported by sufficient evidence ^[6]. Researchers consistently call for larger, longer, and better-controlled trials across all application areas.

Frequently asked questions

What is glutathione and why is it important?

Glutathione (GSH) is a tripeptide made of three amino acids — glutamate, cysteine, and glycine — produced naturally inside virtually every cell in the body. It functions as the cell's primary intracellular antioxidant, neutralising harmful reactive oxygen species, supporting liver detoxification, and helping regulate immune responses. Because it is recycled in a continuous enzymatic cycle, the body maintains a high supply of active GSH under healthy conditions.

Is glutathione the same as a peptide or an amino acid?

Glutathione is a tripeptide — a very small protein-like molecule made of three amino acids linked by peptide bonds. It is not a single amino acid, nor is it a large protein. Its relatively small size and unique γ-glutamyl linkage distinguish it structurally from both simple amino acids and conventional proteins, contributing to its distinctive chemistry and reactivity.

What does glutathione actually do in the body?

Research shows GSH performs several overlapping roles: it directly scavenges reactive oxygen and nitrogen species; it conjugates with toxins and drugs in the liver to help eliminate them; it maintains the redox state of cellular proteins through a process called glutathionylation; it supports immune cell function; and it helps recycle other antioxidants such as vitamins C and E. Its depletion is associated with increased oxidative stress across a wide range of tissues.

Does glutathione lighten skin, and what does the research say?

Cell and animal studies indicate GSH can inhibit tyrosinase — the key enzyme in melanin production — and shift pigment synthesis toward lighter pheomelanin. A 2025 systematic review of five randomised controlled trials found significant reductions in melanin index in participants receiving oral GSH, and a split-face RCT of topical oxidised glutathione also showed statistically significant melanin-index reductions. However, studies are small, results vary, and all observed pigmentation changes appear to reverse after use is stopped.

How does the body make glutathione?

The body synthesises GSH endogenously in a two-step enzymatic process. The first step, catalysed by γ-glutamylcysteinyl ligase (GCL), joins glutamate and cysteine; the second step, catalysed by glutathione synthase, adds glycine to complete the tripeptide. Both steps require ATP. Cysteine availability is often the rate-limiting factor, which is why research into GSH precursors such as N-acetylcysteine (NAC) and glycine has attracted scientific interest.

Does glutathione decline with age?

Research demonstrates that older adults have significantly lower intracellular GSH concentrations than younger adults, primarily because of reduced synthesis linked to decreased availability of glycine and cysteine. This age-related GSH deficiency is associated with elevated oxidative stress, mitochondrial dysfunction, and other biological features considered hallmarks of ageing. Baylor College of Medicine researchers have published RCT data showing that supplementing with GSH precursors can correct this deficiency.

Is oral glutathione absorbed effectively?

Oral bioavailability of intact glutathione is a recognised research limitation. Studies indicate that GSH is substantially broken down in the gastrointestinal tract into its constituent amino acids prior to systemic absorption, which means the body may receive the amino-acid building blocks rather than the intact tripeptide. Some animal studies suggest partial absorption of the intact molecule through the small intestine, but human evidence on this point is inconsistent. Precursor strategies and alternative delivery forms are active areas of investigation.

What is the difference between reduced glutathione (GSH) and oxidised glutathione (GSSG)?

Reduced glutathione (GSH) is the active, antioxidant form bearing a free thiol group (–SH). When GSH donates electrons to neutralise oxidants, two GSH molecules are joined to form glutathione disulfide (GSSG), the oxidised form. The enzyme glutathione reductase uses NADPH to convert GSSG back to two molecules of GSH, maintaining the cycle. The ratio of GSH to GSSG is a widely used laboratory measure of the cell's redox status.

Is glutathione research relevant to liver disease?

Yes. The liver contains the highest concentration of GSH in the body and relies on it heavily for detoxification. Research in NAFLD patients has shown that GSH therapy is associated with improvements in liver enzyme markers such as ALT and reductions in oxidative stress biomarkers, though the human trial data available to date involves small participant numbers and short durations, and larger controlled trials are still needed to confirm these findings.

What are the known limitations of glutathione research?

Key limitations include: the partial degradation of orally administered GSH in the gut, which complicates interpretation of clinical findings; predominantly small, short-duration human trials across all application areas; limited long-term safety data; inconsistent outcomes between studies; and most skin-lightening evidence being restricted to participants with darker Fitzpatrick skin types, limiting generalisability. Researchers and systematic reviewers consistently call for larger, longer, and more rigorously designed trials.

Glossary

Tripeptide

A molecule composed of exactly three amino acid residues joined by peptide bonds; glutathione is a tripeptide of glutamate, cysteine, and glycine.

Reactive Oxygen Species (ROS)

Chemically reactive molecules containing oxygen — such as hydrogen peroxide, superoxide, and hydroxyl radicals — that are produced during normal cellular metabolism and can cause oxidative damage when they accumulate excessively.

Redox Homeostasis

The dynamic equilibrium between oxidising and reducing conditions within a cell, maintained primarily by antioxidant systems including the GSH/GSSG cycle.

Oxidative Stress

A cellular state in which the production of reactive oxygen species outpaces the cell's antioxidant defences, leading to damage of proteins, lipids, and DNA.

Tyrosinase

The rate-limiting enzyme in melanin biosynthesis that oxidises the amino acid tyrosine; glutathione is studied for its ability to inhibit this enzyme and thereby influence skin pigmentation.

Glutathionylation (Protein S-Glutathionylation)

The reversible formation of a mixed disulfide bond between a glutathione molecule and a cysteine residue of a target protein, serving as a post-translational regulatory switch in response to oxidative or nitrosative signals.

GlyNAC

A combination of the amino acid glycine and N-acetylcysteine (a cysteine precursor), studied as a strategy for replenishing intracellular glutathione by supplying its rate-limiting biosynthetic building blocks.

GSH/GSSG Ratio

The ratio of reduced glutathione (GSH) to its oxidised form (GSSG) within cells or blood, widely used in research as a quantitative biomarker of redox status and oxidative stress.

References

1. Preface to the Special Issue 'Glutathione: Chemistry and Biochemistry' — Perjési (2023) — Molecules / PubMed
2. Glutathione: A Naturally Occurring Tripeptide for Functional Metal Nanomaterials — PMC (2025) — PMC / RSC
3. Glutathione: Antioxidant Properties Dedicated to Nanotechnologies — Couto et al. (2018) — Antioxidants (MDPI)
4. Glutathione Metabolism and Its Role in Hepatotoxicity — Pompella et al. (1991) — Pharmacology & Therapeutics / PubMed
5. Glutathione 'Redox Homeostasis' and Its Relation to Cardiovascular Disease — Lushchak et al. (2019) — BioMed Research International / PMC
6. Glutathione as a Skin-Lightening Agent and in Melasma: A Systematic Review — Sarkar et al. (2025) — International Journal of Dermatology (Wiley)
7. Systemic Glutathione as a Skin-Whitening Agent in Adults — Systematic Review (2020) — PMC
8. Skin-Whitening and Skin-Condition-Improving Effects of Topical Oxidized Glutathione: A Double-Blind and Placebo-Controlled Clinical Trial — Watanabe et al. (2014) — Clinical, Cosmetic and Investigational Dermatology (Dove Press)
9. A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease (2025) — Biomedicines (MDPI) / PubMed
10. Efficacy of Glutathione for the Treatment of Nonalcoholic Fatty Liver Disease: An Open-Label, Single-Arm, Multicenter, Pilot Study — Yokohama et al. (2017) — BMC Gastroenterology / PMC
11. Supplementing GlyNAC in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial — Kumar et al. (2023) — Journals of Gerontology / PubMed
12. Glutathione in Our Diet and Its Role in the Body: From Disease Prevention to Anti-Aging — PMC (2025) — PMC
13. Oxidative Stress: Glutathione and Its Potential to Protect Methionine-35 of Aβ Peptide from Oxidation — ACS Omega (2022) — ACS Omega
14. Relationship between Plasma Glutathione Levels and Cardiovascular Disease in a Defined Population: The Hisayama Study (2004) — Stroke / PubMed
15. Glutathione Restores the Mitochondrial Redox Status and Improves the Function of the Cardiovascular System in Old Rats (2023) — Frontiers in Physiology / PMC